|
|
|
|
|
Citalopram
drug data and news
Citalopram drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Citalopram | ||
| Brand Names/Synonyms | CHEMBANK1660; Celexa; Cipram; Citalopram; Citalopram Hydrobromide; Citalopram [Ban:Inn]; Citalopramum [Inn-Latin]; Lexapro; Nitalapram | ||
| Indication | For the treatment of depression | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Citalopram is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). It is used to treat the depression associated with mood disorders. It is also used on occassion in the treatment of body dysmorphic disorder and anxiety. The antidepressant, antiobsessive-compulsive, and antibulimic actions of Citalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. In vitro studies show that Citalopram is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake. Citalopram has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of Citalopram was found to downregulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder. Citalopram does not inhibit monoamine oxidase. | ||
| Mechanism Of Action | The antidepressant, antiobsessive-compulsive, and antibulimic actions of Citalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. Citalopram blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors. SSRIs bind with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs. | ||
| Citalopram News (When available) |
Aurobindo gets Health Canada approval for Citalopram 06 Mar 2006 Aurobindo gets first product approval in Canada 06 Mar 2006 APS: Brain May Be Important Factor In Heart Disease 06 Mar 2006 Bombay Stocks Close Higher 06 Mar 2006 The rally continues; Sensex scales new height 06 Mar 2006 Bentley Pharmaceuticals Provides Update on Product Approvals ... Feb 27, 2006 Aurobindo Pharma gets Canada nod for drug Mar 5, 2006 STAR*D Preliminary Findings Provide Clearer Picture of Major ... Feb 27, 2006 Monoaminergic Treatment of Schizophrenia Feb 27, 2006 Bentley announces score of Spanish generics approvals Feb 28, 2006 Cipralex® - new data supports the superiority of Cipralex® ... Feb 27, 2006 Depression: initial results help determine successful treatments Feb 3, 2006 Psychosis Related to Ropinirole Mar 2, 2006 Trimipramine for Refractory Panic Attacks Mar 2, 2006 Hepatitis C Treatment for People With Severe Mental Illness Feb 28, 2006 Cutting Certain Pills in Half Can Help Reduce Costs Feb 19, 2006 Antidepressants: Are they safe during pregnancy? Feb 22, 2006 Antidepressants in Pregnancy Linked to Newborn Hangover Feb 7, 2006 Madison County cashes in Feb 18, 2006 Baby blues: Big dilemma? Feb 17, 2006 Lower Switch Rate in Depressed Patients With Bipolar II Than ... Feb 14, 2006 Bipolar Disorder Treatment: An Evidence-Based Reality Check Feb 14, 2006 Study: Antidepressants pose risks for newborns 09 Feb 2006 Depression: initial results help determine successful treatments Feb 3, 2006 Antidepressants in Pregnancy Linked to Newborn Hangover Feb 7, 2006 Forest Laboratories, Inc. Reports Q3'06 Diluted Earnings Per Share ... Jan 17, 2006 Identifying Patients with Treatment-Resistant Depression Jan 10, 2006 Guideline Watch: Practice Guideline for the Treatment of Patients ... Jan 23, 2006 Stock Watch Jan 10, 2006 Suicide Risks and SSRIs Jan 17, 2006 Continuity of Antidepressant Treatment for Adults With Depression ... Jan 24, 2006 Brief Reports: Patterns of Psychotropic Medication Use by Race ... Jan 25, 2006 Bharat Forge: Margin pinch Jan 16, 2006 Clinical Guidelines for Psychiatrists for the Use of ... Jan 23, 2006 Excerpts From Night Falls Fast Jan 23, 2006 Govt medicine spending slammed as 'pathetic' Dec 5, 2005 SSRI prescribing up 9.7 percent despite warnings Dec 5, 2005 Credit Control Nov 26, 2005 Big pharma: SSRI risks could limit depression market Nov 25, 2005 Generic Deluge Nov 14, 2005 Evaluation of Reboxetine, a Noradrenergic Antidepressant, for the ... Sep 23, 2005 Cutting into alcoholism Oct 6, 2005 DOV Pharmaceutical, Inc. Announces Phase II Efficacy Results for ... Sep 27, 2005 DOV's antidepressant impresses in phase II trial Sep 28, 2005 Evidence-Based Therapies in Child and Adolescent Psychiatry Oct 3, 2005 Cohen supporters claim police cover-up Oct 4, 2005 UK docs told to hold antidepressants for teens Sep 28, 2005 New Survey Results from the Community Anti-Drug Coalitions of ... Sep 29, 2005 Ranbaxy starts Canadian operations Sep 22, 2005 Generic giant moves in from India Sep 23, 2005 Second-Generation Antidepressants Equally Effective Sep 20, 2005 Ranbaxy Launches in Canada Sep 22, 2005 Antidepressants, Depression and Suicide Sep 12, 2005 State briefs: September 24 Sep 23, 2005 Prevalence and Treatment of Depression in Parkinson’s Disease Sep 24, 2005 Breaking the Teeth -- Grinding Habit Sep 22, 2005 Bilateral Exophthalmos and Depression: Not Always Endocrine ... Sep 24, 2005 Many meds don't mix with the sun Sep 21, 2005 Moria and Witzelsücht from Frontotemporal Dementia Sep 24, 2005 Man died from lethal overdose Sep 22, 2005 First trimester antidepressant risk Sep 14, 2005 Childhood Depression Is Understudied and Under-treated Sep 9, 2005 | ||
| Dosage Forms | Oral solution and tablets | ||
| Drug_Category | Antidepressants; Selective Serotonin Reuptake Inhibitors (SSRIs); ATC:N06AB04; ATC:N06AB10 | ||
| Absorption | 80% | ||
| Interactions | Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers | ||
| Toxicity | sexual dysfunction, especially ejaculatory difficulties in men. Commonly, citalopram may cause drowsiness, dry mouth, nausea, and sleeping problems | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile | ||
| Chemical Formula | C20H21FN2O | ||
| Molecular Weight | 324.392 g/mol | ||
| Smiles String | CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F | ||
| Melting Point | 182-183°C | ||
| Water Solubility | 31 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 4.222 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | liver | ||
| Half Life | 35 hours | ||
| Protein Binding [%] | 50% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Citalopram.html http://www.rxlist.com/cgi/generic/citalo.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00147 | ||
| CAS Registry Number | 59729-33-8 | ||
| KEGG Compound ID | C07572 | ||
| PubChem ID | SID:183529 | ||
| PharmGKB ID | PA449015 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2248051 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |